Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United States, Canada, United Kingdom, Germany, France, China, India, Japan Company Analysis March 2018
Table of Content S.No Particulars Page No. 1. Research Methodology 19 2. Executive Summary 20 3. Strategic Recommendation 21 3.1 Asia Pacific Region to witness fastest growth for HPV Treatment 22 3.2 Male segment is anticipated to witness highest growth 23 4. HPV Vaccine Market: Product Outlook 24 5. Global HPV Vaccine Market: Growth and Forecast 31 5.1 Global HPV Vaccine Market, By Value (2012-2016) 32 5.2 Global HPV Vaccine Market, By Value (2017-2022) 40 5.3 Global HPV Vaccine Market - By End-User, By Value 41 5.3.1 Global HPV Vaccine Market, By Value, % (2016) 41 5.3.2 Global HPV Vaccine Market, By Value, % (Forecast 2022F) 42 2
Table of Content S.No Particulars Page No. 5.4 Global HPV Vaccine Market, By End-User, By Value (2012-2022) 43 5.4.1 Male, By Value (2012-2022) 43 5.4.2 Female, By Value (2012-2022) 43 5.5 Global HPV Vaccine Market, By Age-Group, By Value (2012-2022) 44 5.5.1 Adolescent, By Value (2012-2022) 44 5.5.2 Adult, By Value (2012-2022) 44 6. North America HPV Vaccine Market: Growth and Forecast 46 6.1 North America HPV Vaccine Market, By Value (2012-2016) 47 6.2 North America HPV Vaccine Market, By Value (2017-2022) 50 6.3 North America HPV Vaccine Market - By End-User, By Value 51 6.3.1 North America HPV Vaccine Market, By Value, % (2016) 51 6.3.2 North America HPV Vaccine Market, By Value, % (Forecast 2022F) 52 6.4 North America HPV Vaccine Market, By End-User, By Value (2012-2022) 53 6.4.1 Male, By Value (2012-2022) 53 6.4.2 Female, By Value (2012-2022) 53 3
Table of Content S. No Particulars Page No. 6.5 North America HPV Vaccine Market, By Age-Group, By Value (2012-2022) 54 6.5.1 Adolescent, By Value (2012-2022) 54 6.5.2 Adult, By Value (2012-2022) 54 6.6 North America HPV Vaccine Market: Country Analysis (U.S., Canada) 55 6.6.1 North America HPV Vaccine Market, Country Share, 2016 (% of Total) 55 6.6.2 North America HPV Vaccine Market, Country Share, 2022 (% of Total) 55 6.7 U.S. HPV Vaccine Market: Growth and Forecast 57 6.7.1 U.S. HPV Vaccine Market, By Value (2012-2016) 58 6.7.2 U.S. HPV Vaccine Market, By Value (2017-2022) 58 6.8 U.S. HPV Vaccine Market - By End-User, By Value 64 6.8.1 Male, By Value (2012-2022) 64 6.8.2 Female, By Value (2012-2022) 64 6.9 Canada HPV Vaccine Market: Growth and Forecast 66 6.9.1 Canada HPV Vaccine Market, By Value (2012-2016) 67 6.9.2 Canada HPV Vaccine Market, By Value (2017-2022) 67 6.10 Canada HPV Vaccine Market - By End-User, By Value 74 6.10.1 Male, By Value (2012-2022) 74 6.10.2 Female, By Value (2012-2022) 74 4
Table of Content S.No Particulars Page No. 7. Europe HPV Vaccine Market: Growth and Forecast 75 7.1 Europe HPV Vaccine Market, By Value (2012-2016) 76 7.2 Europe HPV Vaccine Market, By Value (2017-2022) 80 7.3 Europe HPV Vaccine Market - By End-User, By Value 81 7.3.1 Europe HPV Vaccine Market, By Value, % (2016) 81 7.3.2 Europe HPV Vaccine Market, By Value, % (Forecast 2022F) 82 7.4 Europe HPV Vaccine Market, By End-User, By Value (2012-2022) 83 7.4.1 Male, By Value (2012-2022) 83 7.4.2 Female, By Value (2012-2022) 83 7.5 Europe HPV Vaccine Market, By Age-Group, By Value (2012-2022) 84 7.5.1 Adolescent, By Value (2012-2022) 84 7.5.2 Adult, By Value (2012-2022) 84 7.6 Europe HPV Vaccine Market: Country Analysis (U.K., Germany, France & Rest of Europe) 85 7.6.1 Europe HPV Vaccine Market, Country Share, 2016 (% of Total) 85 7.6.2 Europe HPV Vaccine Market, Country Share, 2022 (% of Total) 85 5
Table of Content S. No Particulars Page No. 7.7 U.K. HPV Vaccine Market: Growth and Forecast 88 7.7.1 U.K. HPV Vaccine Market, By Value (2012-2016) 89 7.7.2 U.K. HPV Vaccine Market, By Value (2017-2022) 89 7.8 U.K. HPV Vaccine Market - By End-User, By Value 94 7.8.1 Male, By Value (2012-2022) 94 7.8.2 Female, By Value (2012-2022) 94 7.9 Germany HPV Vaccine Market: Growth and Forecast 96 7.9.1 Germany HPV Vaccine Market, By Value (2012-2016) 97 7.9.2 Germany HPV Vaccine Market, By Value (2017-2022) 97 7.10 Germany HPV Vaccine Market - By End-User, By Value 104 7.10.1 Male, By Value (2012-2022) 104 7.10.2 Female, By Value (2012-2022) 104 6
Table of Content S. No Particulars Page No. 7.11 France HPV Vaccine Market: Growth and Forecast 105 7.11.1 France HPV Vaccine Market, By Value (2012-2016) 105 7.11.2 France HPV Vaccine Market, By Value (2017-2022) 106 7.12 France HPV Vaccine Market - By End-User, By Value 111 7.12.1 Male, By Value (2012-2022) 111 7.12.2 Female, By Value (2012-2022) 111 7.13 Rest of Europe HPV Vaccine Market: Growth and Forecast 112 7.13.1 Rest of Europe HPV Vaccine Market, By Value (2012-2016) 112 7.13.2 Rest of Europe Vaccine Market, By Value (2017-2022) 112 8. Asia-Pacific HPV Vaccine Market: Growth and Forecast 113 8.1 Asia-Pacific HPV Vaccine Market, By Value (2012-2016) 114 8.2 Asia-Pacific HPV Vaccine Market, By Value (2017-2022) 120 8.3 Asia-Pacific HPV Vaccine Market - By End-User, By Value 121 8.3.1 Asia-Pacific HPV Vaccine Market, By Value, % (2016) 121 8.3.2 Asia-Pacific HPV Vaccine Market, By Value, % (Forecast 2022F) 122 7
Table of Content S.No Particulars Page No. 8.4 Asia-Pacific HPV Vaccine Market, By End-User, By Value (2012-2022) 123 8.4.1 Male, By Value (2012-2022) 123 8.4.2 Female, By Value (2012-2022) 123 8.5 Asia-Pacific HPV Vaccine Market, By Age-Group, By Value (2012-2022) 124 8.5.1 Adolescent, By Value (2012-2022) 124 8.5.2 Adult, By Value (2012-2022) 124 8.6 Asia-Pacific HPV Vaccine Market: Country Analysis (Japan, China, India) 125 8.6.1 Asia-Pacific HPV Vaccine Market, Country Share, 2016 (% of Total) 125 8.6.2 Asia-Pacific HPV Vaccine Market, Country Share, 2022 (% of Total) 125 8.7 Japan HPV Vaccine Market: Growth and Forecast 127 8.7.1 Japan HPV Vaccine Market, By Value (2012-2016) 128 8.7.2 Japan HPV Vaccine Market, By Value (2017-2022) 128 8.8 Japan HPV Vaccine Market - By End-User, By Value 131 8.8.1 Male, By Value (2012-2022) 11 8.8.2 Female, By Value (2012-2022) 131 8
Table of Content S. No Particulars Page No. 8.9 China HPV Vaccine Market: Growth and Forecast 132 8.9.1 China HPV Vaccine Market, By Value (2012-2016) 133 8.9.2 China HPV Vaccine Market, By Value (2017-2022) 133 8.10 China HPV Vaccine Market - By End-User, By Value 139 8.10.1 Male, By Value (2012-2022) 139 8.10.2 Female, By Value (2012-2022) 139 8.11 India HPV Vaccine Market: Growth and Forecast 140 8.11.1 India HPV Vaccine Market, By Value (2012-2016) 141 8.11.2 India HPV Vaccine Market, By Value (2017-2022) 141 8.12 India HPV Vaccine Market - By End-User, By Value 147 8.12.1 Male, By Value (2012-2022) 147 8.12.2 Female, By Value (2012-2022) 147 9. ROW HPV Vaccine Market: Growth and Forecast 148 9.1 ROW HPV Vaccine Market, By Value (2012-2016) 149 9.2 ROW HPV Vaccine Market, By Value (2017-2022) 150 9
Table of Content S. No Particulars Page No. 10. Market Dynamics 153 10.1 Increasing healthcare awareness about Sexually Transmissible Disease 155 10.2 Development of Healthcare Infrastructure 156 10.3 Rising global healthcare expenditure and favorable reimbursed policies 157 11. Market Restraints 158 12. Market Trends 160 13. SWOT Analysis HPV Vaccine Market 163 14. Porter s Five Forces Analysis 165 15. Policy and Regulatory Landscape 167 16. Company Profile 177 16.1 Merck and Co 16.2 GlaxoSmithKline 178 181 17. About Us 184 10
List of Figures Figure No. Figure Title Page No. Figure 1: Global HPV vaccine Market Size, By Value, 2012-2016 (USD Million) 32 Figure 2: World Male Population Estimates, 2017 (In Millions) 33 Figure 3: World Female Population Estimates, 2017 (In Millions) 33 Figure 4: World Female Population, Age 10-14 Years Old (2012-2016) 34 Figure 5: World Male Population, Age 10-14 Years Old (2012-2016) 34 Figure 6: Global Healthcare Expenditure, 2012-2016 (In Trillion) 36 Figure 7: Top 10 Most Frequent Cancer in Females, World, (Age standardised incidence rate per 100,000 women) 37 Figure 8: Top 10 Most Frequent Cancer Deaths in Females, World, (Age standardised incidence rate per 100,000 women) 37 Figure 9: Age-Standardized Cervical Cancer Incidence Rate (per 100,000 women per year), By Region 37 Figure 10: HPV Related Cancer Cases in Women/ Year, 530,000 38 Figure 11: HPV Related Cancer Cases in Men/ Year, 39,000 38 Figure 12: Global HPV Vaccine Market Size, By Value, 2017-2022 (USD Million) 40 Figure 13: Global HPV vaccine Market Size, By End-User, 2016 (%) 41 Figure 14: Global HPV Vaccine Market Size, By End-User, 2022 (%) 42 Figure 15: Global HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million) 43 Figure 16: Global HPV Vaccine Market By Age Group, By Value 2012-2022 (USD Million) 44 Figure 17: North America HPV Vaccine Market Size, By Value, 2012-2016 (USD Million) 47 Figure 18: North America GDP, 2012-2015 (USD Trillion) 48 Figure 19: North America GDP, By Select Country, 2016 (USD Trillion) 48 11
List of Figures Figure No. Figure Title Page No. Figure 20: North America Healthcare Cost Per Capita, By Select Country, 2016 (USD) 48 Figure 21: North America Female Population, Age 10-14 Years Old (2012-2016) 49 Figure 22: North America Male Population, Age 10-14 Years Old (2012-2016) 49 Figure 23: North America HPV Vaccine Market Size, By Value, 2017-2022(USD Million) 50 Figure 24: North America HPV vaccine Market Size, By End-User, 2016 (%) 51 Figure 25: North America HPV Vaccine Market Size, By End-User, 2022 (%) 52 Figure 26: North America HPV Vaccine Market, End-User, By Value 2012-2022 (USD Million) 53 Figure 27: North America HPV Vaccine Market, By Age Group, By Value 2012-2022 (USD Million) 54 Figure 28: North America HPV Vaccine Market, Country Share, 2016 (% of Total) 55 Figure 29: North America HPV Vaccine Market, Country Share, 2022 (% of Total) 55 Figure 30: U.S. HPV Vaccine Market Size, By Value, 2012-2022 (USD Million) 58 Figure 31: U.S. Female Population, Age 10-14 Years Old (2012-2016) 61 Figure 32: U.S. Male Population, Age 10-14 Years Old (2012-2016) 61 Figure 33: U.S. Per Capita Healthcare Expenditure, 2012-2016 (In USD) 61 Figure 34: U.S. HPV vaccine Market Size, By End-User, 2016 (%) 62 Figure 35: U.S. HPV Vaccine Market Size, By End-User, 2022 (%) 63 Figure 36: U.S. HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million) 64 Figure 37: Annual Sales of Cervarix vaccines in U.S., (In Million USD) 2012-2016 65 Figure 38: Canada HPV Vaccine Market Size, By Value, 2012-2022 (USD Million) 67 Figure 39: Canada Female Population, Age 10-14 Years Old (2012-2016) 68 12
List of Figures Figure No. Figure Title Page No. Figure 40: Canada Male Population, Age 10-14 Years Old (2012-2016) 68 Figure 41: Normal Cytology 70 Figure 42: Low-Grade lesions 70 Figure 43: High-Grade lesions 70 Figure 44: Cervical Cancer 70 Figure 45: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016) 71 Figure 46: Canada HPV vaccine Market Size, By End-User, 2016 (%) 72 Figure 47: Canada HPV Vaccine Market Size, By End-User, 2022 (%) 73 Figure 48: Canada HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million) 74 Figure 49: Europe HPV Vaccine Market Size, By Value, 2012-2016 (USD Million) 76 Figure 50: Europe, Female Population aged 15+, By Region, 2017 (In Millions) 77 Figure 51: European Union, Per Capita Healthcare Expenditure, 2012-2014 (In USD) 77 Figure 52: Europe Female Population, Age 10-14 Years Old (2012-2016) 77 Figure 53: Europe Male Population, Age 10-14 Years Old (2012-2016) 77 Figure 54: Europe, GDP, By Select Country, 2016 (USD Billion) 78 Figure 55: Europe Health Spending Per Capita, By Select Country, 2016 (USD) 78 Figure 56: Europe HPV Vaccine Market Size, By Value, Forecast, 2017-2022 (USD Million) 80 Figure 57: Europe HPV Vaccine Market Size, By End-User, 2016 (%) 81 Figure 58: Europe HPV Vaccine Market Size, By End-User, 2022 (%) 82 Figure 59: Europe HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million) 83 Figure 60: Europe HPV Vaccine Market By Age Group, By Value 2012-2022 (USD Million) 84 13
List of Figures Figure No. Figure Title Page No. Figure 61: Europe HPV Vaccine Market, Country Share, 2016 (% of Total) 85 Figure 62: Europe HPV Vaccine Market, Country Share, 2022 (% of Total) 85 Figure 63: Annual Sales of Cervarix vaccines in Europe, (In Million USD) 2012-2016 86 Figure 64: U.K. HPV Vaccine Market Size, By Value, 2012-2022 (USD Million) 89 Figure 65: U.K. Female Population, Age 10-14 Years Old (2012-2016) 91 Figure 66: U.K. Male Population, Age 10-14 Years Old (2012-2016) 91 Figure 67: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016) 91 Figure 68: U.K., Per Capita Healthcare Expenditure, 2012-2016 (In USD) 91 Figure 69: U.K. HPV Vaccine Market Size, By End User, 2016 (%) 92 Figure 70: U.K. HPV Vaccine Market Size, By End User, 2022 (%) 93 Figure 71: U.K. HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million) 94 Figure 72: Germany HPV Vaccine Market Size, By Value, 2012-2022 (USD Million) 97 Figure 73: Germany Female Population, Age 10-14 Years Old (2012-2016) 98 Figure 74: Germany Male Population, Age 10-14 Years Old (2012-2016) 98 Figure 75: Germany Per Capita Healthcare Expenditure, 2012-2014 (In USD) 98 Figure 76: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016) 99 Figure 77: Germany HPV Vaccine Market Size, By End User, 2016 (%) 102 Figure 78: Germany HPV Vaccine Market Size, By End User, 2022 (%) 103 Figure 79: Germany HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million) 104 Figure 80: France HPV Vaccine Market Size, By Value, 2012-2022 (USD Million) 106 14
List of Figures Figure No. Figure Title Page No. Figure 81: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016) 107 Figure 82: France Female Population, Age 10-14 Years Old (2012-2016) 108 Figure 83: France Male Population, Age 10-14 Years Old (2012-2016) 108 Figure 84: France Per Capita Healthcare Expenditure, 2012-2014 (In USD) 108 Figure 85: France HPV Vaccine Market Size, By End-User, 2016 (%) 109 Figure 86: France HPV Vaccine Market Size, By End-User, 2022 (%) 110 Figure 87: France HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million) 111 Figure 88: Rest of Europe HPV Vaccine Market Size, By Value, 2012-2022 (USD Million) 112 Figure 89: Asia-Pacific HPV Vaccine Market Size, By Value, 2012-2016 (USD Million) 114 Figure 90: Asia Female Population, Age 10-14 Years Old (2012-2016) 118 Figure 91: Asia Male Population, Age 10-14 Years Old (2012-2016) 118 Figure 92: APAC, GDP, By Select Country, 2016 (USD Billion) 119 Figure 93: APAC Health Expenditure Per Capita, Public and Private, By Select Country, 2016 (USD) 119 Figure 94: Asia-Pacific HPV Vaccine Market Size, By Value, 2017-2022 (USD Million) 120 Figure 95: Asia-Pacific HPV Vaccine Market Size, By End-User, 2016 (%) 121 Figure 96: Asia-Pacific HPV Vaccine Market Size, By End-User, 2022 (%) 122 Figure 97: Asia-pacific HPV Vaccine - End-User, By Value 2012-2022 (USD Million) 123 Figure 98: Asia-Pacific HPV Vaccine Market Age Group, By Value 2012-2022 (USD Million) 124 Figure 99: Asia-Pacific HPV Vaccine Market, Country Share, 2016 (% of Total) 125 Figure 100: Asia-Pacific HPV Vaccine Market, Country Share, 2022 (% of Total) 125 15
List of Figures Figure No. Figure Title Page No. Figure 101: Japan HPV Vaccine Market Size, By Value, 2012-2022 (USD Million) 128 Figure 102: Japan HPV Vaccine Market Size, By End-User, 2016 (%) 129 Figure 103: Japan HPV Vaccine Market Size, By End-User, 2022 (%) 130 Figure 104: Japan HPV Vaccine - End-User, By Value 2012-2022 (USD Million) 131 Figure 105: China HPV Vaccine Market Size, By Value, 2012-2022 (USD Million) 133 Figure 106: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016) 135 Figure 107: China Female Population, Age 10-14 Years Old (2012-2016) 136 Figure 108: China Male Population, Age 10-14 Years Old (2012-2016) 136 Figure 109: China Per Capita Healthcare Expenditure, 2012-2014 (In USD) 136 Figure 110: China HPV Vaccine Market Size, By End-User, 2016 (%) 137 Figure 111: China HPV Vaccine Market Size, By End-User, 2022 (%) 138 Figure 112: China HPV Vaccine - By End-User, By Value 2012-2022 (USD Million) 139 Figure 113: India HPV Vaccine Market Size, By Value, 2012-2022 (USD Million) 141 Figure 114: India Female Population, Age 10-14 Years Old (2012-2016) 143 Figure 115: India Male Population, Age 10-14 Years Old (2012-2016) 143 Figure 116: Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016) 143 Figure 117: India HPV Vaccine Market Size, By End-User, 2016 (%) 144 Figure 118: India HPV Vaccine Market Size, By End-User, 2022 (%) 145 Figure 119: India HPV Vaccine - By End-User, By Value 2012-2022 (USD Million) 146 Figure 120: Rest of Asia-Pacific HPV Vaccine Market Size, By Value, 2012-2022 (USD Million) 147 16
List of Figures Figure No. Figure Title Page No. Figure 121: ROW HPV Vaccine Market Size, By Value, 2012-2016 (USD Million) 149 Figure 122: ROW HPV Vaccine Market Size, By Value, 2017-2022 (USD Million) 150 Figure 123: Africa Female Population, Age 10-14 Years Old (2012-2016) 151 Figure 124: Africa Male Population, Age 10-14 Years Old (2012-2016) 151 Figure 125: Prevalence of Cervical Cancer, among women in Africa (Patients per 100,000 (2012-2016) 151 Figure 126: Prevalence of Cervical Cancer among female in Brazil (Patients per 100,000 (2012-2016) 152 Figure 127: Global Healthcare Expenditure, 2012-2016 (In Trillion) 157 Figure 128: Annual Sales of HPV vaccines, By leading players, (In Million USD) 2012-2016 175 Figure 129: Market Share of Leading players in HPV vaccine market, 2016 176 Figure 130: Merck & Co., Net Sales, 2012-2016 (In million USD) 179 Figure 131: Merck & Co, Net Sales of Gardasil/Gardasil 9, 2012-2016 (In million USD) 179 Figure 132: Merck & Co., Net Sales, By Geographic Location, % Share 2016 179 Figure 133: Merck & Co., Net Revenue, By Business Segment, % Share 2016 179 Figure 134: GlaxoSmithKline Annual Revenue, 2014-2016 (USD Million) 182 Figure 135: Sales from Hepatitis Vaccination, GlaxoSmithKline, 2015-2016 (USD Million) 182 Figure 136: GlaxoSmithKline Sales, By Region, 2016 (%) 182 Figure 137: GlaxoSmithKline, Sales, By Segment 2016 (%) 182 17
List of Tables Table No. Table Title Page No. Table A: Globally approved HPV vaccines, 2016 29 Table B: HPV Vaccine Market Segmentation Flowchart 30 Table C: Estimated number of HPV Associated cases in 2017 59 Table D: Estimated new HPV related cancers cases, 2011, 2012 & 2016 69 Table E: Newly registered diagnosed cases of HPV related cancer in England, 2016 90 Table F: Estimated and Predicted HPV related cancer among male and female, 2011, 2012 & 2016 100 Table G: Estimated and Predicted HPV related cancer among female, 2011, 2012 & 2016 100 Table H: Key Statistics on HPV burden in Asia 114 Table I: Estimated HPV related New Cancer Cases and Deaths (Thousands), By Sex, 2015 135 18
Research Methodology For our study on Global HPV Vaccine Market, we have conducted comprehensive secondary research followed by an extensive primary research. In the process of secondary research, we have scrutinized industry documents, accessed from open sources, premium paid databases (Bloomberg, Thomson Reuters, Factiva) and our internal knowledge base. In the process of primary research, we have interviewed various industry experts across the value chain of HPV Vaccine Market. Market size of the actual period (2012-2016) has been evaluated on the basis of growth trends of the industry in the last five years, and confirming the findings through primary research. Annual reports of the companies are scanned to further validate the market size and to estimate the size of various other end-user sectors. Market sizing and growth in the forecast period (2017-2022) is estimated through product mapping, application in end-user industries, growth of allied sectors and historical growth pattern of the industry. All the relevant data points/ statistics in the forecast period are validated through relevant and reliable primary sources. Report Focus: HPV Vaccine Market -By Region- North America, Europe, APAC and ROW -By Country - United States, Canada, United Kingdom, Germany, France, China, India, Japan Company Analysis Companies Contacted: GlaxoSmithKline Pharmaceuticals Ltd 19
Global HPV Vaccine Market Overview Rising Prevalence of Sexually Transmissible Diseases, increasing global adolescence population, growing healthcare burden due to Sexually Transmissible virus propelled the market growth Figure : Global HPV vaccine Market Size, By Value, 2012-2016 (USD Million) CAGR 2012-2016 HPV: xx%; 2012 2013 2014 2015 2016 Source: Azoth Analytics Estimates xxxxx 20
Global HPV Vaccine Market - By Age Group, By Value Figure : Global HPV Vaccine Market By Age Group, By Value 2012-2022 (USD Million) CAGR 2012-2016 Adolescent: xx%; Adult: xx% CAGR 2017-2022 Adolescent: xx%; Adult: xx% 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Source: Azoth Analytics Estimates xxxxx 21
North America HPV Vaccine Market - By End-User, By Value Higher healthcare burden due to Cervical Cancer caused by HPV virus is attributed to the larger market share in female segment Figure : North America HPV vaccine Market Size, By End-User, 2016 (%) Key Drivers Male xxxxx xxxxx Female xxxxx xxxxx Source: Azoth Analytics Estimates 22
Germany HPV Vaccine Market - By End-User, By Value Figure : Germany HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million) CAGR 2012-2016 Male: xx%; Female: xx% CAGR 2017-2022 Male: xx%; Female: xx% 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Source: Azoth Analytics Estimates xxxxx 23
Asia-Pacific HPV Vaccine Market - By Country Share Figure : Asia-Pacific HPV Vaccine Market, Country Share, 2016 (% of Total) Figure : Asia-Pacific HPV Vaccine Market, Country Share, 2022 (% of Total) Japan Japan China China India India Others Others Source: Azoth Analytics Estimates Source: Azoth Analytics Estimates 24
About Azoth Analytics Pvt Ltd. Azoth Analytics is a business research and analytics firm that creates in-depth research res and provides customized research solutions and consultancy services. Verticals in which Azoth Analytics specializes include healthcare and Pharmaceutical, oil and gas, retail, chemicals, automotive, FMCG, food & beverages and technology. Azoth creates comprehensive and in-depth research res by recording, interpreting and analyzing information. Strategic market sizing and data dredging End Users include secondary research, and primary research (interviews with management personnel and industry experts). Disclaimer: Azoth Analytics report information is based mainly on interviews and therefore, is subject to fluctuation. Azoth Analytics therefore, takes no responsibility for any incorrect information supplied to us by industry experts, manufacturers or User.. Also, analysis provided in the re are meant for customers internal use only and not for general publication or disclosure to third parties. 25